ADC Therapeutics Accelerates R&D with Genedata Biologics

Enterprise software solution streamlines development of breakthrough antibody drug conjugate (ADC) therapies for cancer treatment

April 16, 2024
Basel, Switzerland

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, announced today that ADC Therapeutics, a commercial-stage biotechnology company and pioneer in the field of antibody drug conjugates (ADCs), has successfully deployed Genedata Biologics^® to streamline the development of next-generation ADCs for the treatment of hematological malignancies and solid tumors.

“We are pleased that ADC Therapeutics has chosen Genedata Biologics to automate and digitalize their antibody drug conjugates research operations,” said Othmar Pfannes, Ph.D., CEO of Genedata. “The implementation of the Genedata platform by yet another leading ADC company underscores the quality of our software for innovative conjugate-based drugs such as antibody, RNA, or peptide conjugates. Our ongoing commitment involves further investment in the Genedata Biopharma Platform to support global customers in advancing new drug modalities with intricate designs and unique properties, so they can accelerate therapeutic progress and deliver novel treatments to patients more efficiently.”

Genedata Biologics, the market-leading R&D workflow platform, supports ADC Therapeutics in building and progressing a pipeline of proprietary ADC candidates for cancer treatment. The regulatory approval of ADC Therapeutics’ first drug, ZYNLONTA^®, just 10 years after the company’s founding, has validated the success of the ADC Therapeutic proprietary technology. Since then, ADC Therapeutics has diversified their product portfolio to include alternative formats and linker-payload technology. This expansion of technologies and growth of research capabilities led them to choose Genedata Biologics as their enterprise research data management solution to streamline increasingly complex ADC development workflows and protect their intellectual property. Genedata Biologics is used for tracking and analyzing production of candidate molecules, including expression, purification, conjugation, and assay analytics. The platform is fully integrated with ADC Therapeutics’ laboratory instruments and IT infrastructure, such as their ELN, to ensure full data traceability and integrity.

“As we scaled up our ADC discovery and development operations, we realized that a robust structured data management system such as Genedata Biologics was essential,” said Patrick van Berkel, Ph.D., Chief Scientific Officer of ADC Therapeutics. “When exploring the market, we were thrilled to find a commercial digital platform that is not only purpose-built for ADC workflows but can even support our proprietary conjugation and linker technologies out-of-the-box. After a smooth deployment, our scientists now have real-time access to all critical data, which enables fully informed decision-making. Today, all our novel ADCs are registered in Genedata, and the platform’s end-to-end capabilities have transformed our research operations, enabling us to systematically advance our next-generation ADC candidates to the clinic.”

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.

ZYNLONTA^® is a registered trademark of ADC Therapeutics SA.